Blog

How immune cell baselines may predict CD22 therapy outcomes in Pediatric Cancer – NCI Center for Cancer Research

Nirali Shah/npr.org

Apr 22, 2025, 11:06

How immune cell baselines may predict CD22 therapy outcomes in Pediatric Cancer – NCI Center for Cancer Research

NCI Center for Cancer Research shared a post on LinkedIn:

“CD22 CAR T-cell immunotherapy is an effective treatment for several types of cancer, with a recent clinical trial showing a 70% response rate.

Researchers wanted to know more about why 30% of patients’ cancers didn’t respond: the answer may lie in the baseline condition of their immune cells. Read more about this CCR study, led by Nirali Shah, from our Pediatric Oncology Branch.

Learn more about research in our Pediatric Oncology Branch.

Image: Microscopy image of B-cell acute lymphoblastic leukemia.

Credit: iStock.”

How immune cell baselines may predict CD22 therapy outcomes in Pediatric Cancer - NCI Center for Cancer Research

cancer CAR T-CELL CD22 fight against cancer Global fight against cancer immunotherapy NCI Center for Cancer Research Nirali Shah OncoDaily Oncology pediatric oncology

Oncologist Near Me – Wafik S. El-Deiry: A Global Leader in Translational Oncology and Cancer Research

In Memory of Bob Marley: His Battle with Melanoma and the Importance of Early Detection

Who From Oncology is Featured in TIME100 Health 2025?

FDA Announces Aggressive Timeline to Scale 1st AI-Assisted Scientific Review Pilot

The Evolving Therapeutic Revolution in Adult Acute Lymphoblastic Leukemia